Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: A report from the Children's Cancer Group

Journal of Clinical Oncology

Volumn 15, Issue 6, 1997, Pages 2222-2230

  Nachman, James ^a   Sather, Harland N ^a   Gaynon, Paul S ^a   Lukens, John N ^a   Wolff, Lawrence ^a   Trigg, Michael E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; AVASCULAR NECROSIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CLINICAL FEATURE; FEMALE; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SKULL IRRADIATION; TREATMENT PLANNING;

EID: 0030915171     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.6.2222     Document Type: Article

References (15)

1. Riehm H, Feickert HJ, Schrappe M, et al: Therapy results in five ALL-BFM studies since 1970: Implications of risk factors for prognosis. Hamatol Bluttransfus 30:139-146, 1987
2. Gajjar A, Ribeiro R, Hancock ML, et al: Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood 86:1292-1295, 1995
3. Gaynon PS, Bleyer WA, Steinherz PG, et al: Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 18:273-279, 1990
4. Steinherz PG, Gaynon PS, Breneman JC, et al: Cytoreduction and prognosis in acute lymphoblastic leukemia - The importance of early marrow response: Report from the Childrens Cancer Group. J Clin Oncol 14:389-398, 1996
5. Gaynon PS, Steinherz PG, Bleyer WA, et al: Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: A follow-up report of the Childrens Cancer Group study CCG-106. J Clin Oncol 11:2234-2242, 1993
6. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
7. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
8. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1-39, 1977
9. Kaspers GJL, Veerman ASP, Pieters R, et al: In vitro drug resistance profile: Strongest prognostic factor in childhood acute lymphoblastic leukemia. Blood 84:516a, 1994 (suppl 1, abstr 2048)
10. Tubergen DG, Gilchrist GS, O'Brien RT, et al: Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: A Childrens Cancer Group phase III trial. J Clin Oncol 11:527-537, 1993
11. Reiter A, Schrappe M, Ludwig WD, et al: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84:3122-3133, 1994
12. Baum E, Nachman J, Ramsay N, et al: Prolonged second remission in childhood acute lymphocytic leukemia: A report from the Childrens Cancer Study Group. Med Pediatr Oncol 11:1-7, 1983
13. Schrappe M, Reiter A, Sauter S, et al: Konzeption und Zwischenergebnis der therapiestudie ALL-BFM 90 zur behandlung der akuten lymphoblastichen leukamie bei kindem und jugendlichen; die bedeutung des initialen therapieansprechens in Blut und Knochenmark. Klin Padiatr 206:208-221, 1994
14. Schorin M, Blattner S, Celber R, et al: Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium protocol 85-01. J Clin Oncol 12:740-747, 1994
15. Lauer S, Pinkel D, Buchannan R, et al: Cytosine arabinoside/ cyclophosphamide pulses during continuation therapy for childhood acute lymphoblastic leukemia. Cancer 60:2366-2371, 1987